

**Question for written answer E-001553/2015
to the Commission**
Rule 130
Lola Sánchez Caldentey (GUE/NGL)

Subject: Access to drugs and the TTIP

The impact of the TTIP will be felt beyond the borders of the European Union and the United States of America because the enormous significance of both parties in world trade means that the treaty will set global standards.

In terms of global health and access to drugs, the treaty could, by increasing restrictions and controls on patents and intellectual property, lead to a drastic rise in the price of drugs because there will be more obstacles to the development of generics.

Article 35 of the Charter of Fundamental Rights of the European Union, on health protection, states that 'everyone has the right of access to preventative health care and the right to benefit from medical treatment', and that this must always be provided in such a way as to ensure 'a high level of human health protection'.

How is the EU going to prevent the creation of pharmaceutical monopolies that go against patients' interests, so as to ensure respect of Article 35 of the Charter of Fundamental Rights of the European Union?